2 news items
Prothena Announces Review On Birtamimab Mechanism Of Action And Pharmacological Characteristics Published In Leukemia & Lymphoma
PRTA
15 Apr 24
survival benefit in patients with Mayo Stage IV AL amyloidosis, which was demonstrated in a post hoc analysis of the Phase 3 VITAL placebo-controlled
Prothena Announces Review on Birtamimab Mechanism of Action and Pharmacological Characteristics Published in Leukemia & Lymphoma
PRTA
15 Apr 24
and is the only treatment that has shown a significant survival benefit in patients with Mayo Stage IV AL amyloidosis, which was demonstrated in a post hoc
- Prev
- 1
- Next